Healthcare Triangle Announces $3 Million Cloud DevOps Managed Services Agreement

2 years ago

Company’s HITRUST-certified Cloud DevOps Managed Services enable new customer to quickly adopt and deploy cloud solutions in a secure, compliant,…

TELA Bio’s OviTex® Reinforced Tissue Matrix to be Featured in Three Case Reports at SAGES 2023

2 years ago

Presentations highlight utility of this advanced hernia reinforcement material for robotic proceduresMALVERN, Pa., March 29, 2023 (GLOBE NEWSWIRE) -- TELA…

Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference

2 years ago

BOSTON, March 29, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives…

Bioxytran Announces Positive Phase 2 Trial Results were Featured in “Vaccines” a Peer-Reviewed Journal

2 years ago

Complete elimination of viral load in 100% of patients at day 7 vs 6% in placebo (p=.001)Complete elimination of most…

Breckenridge Distillery Establishes March 31st as National Après Day

2 years ago

The World’s Highest Distillery Launches First Ever National Après Day in the U.S. and Celebrates #AprèsAnywhere Campaign Breckenridge Distillery Launches #APRESANYWHERE…

Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.

2 years ago

STRASBOURG, France, March 29, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the…

Teleflex Selects GORE® SEAMGUARD® Bioabsorbable Staple Line Reinforcement Material for Use with Innovative Titan SGS® Stapler

2 years ago

Product Pairing Offers an Impactful Partnership for Bariatric SurgeryWAYNE, Pa., March 29, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX),…

BiomX Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

2 years ago

Announced Positive Results from Part 1 of Ongoing Phase 1b/2a Trial of BX004 for Treatment of Lung Infections in Cystic…

Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed / Refractory CD123-Positive Acute Myeloid Leukemia

2 years ago

HEIDELBERG, Germany, March 29, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients…